Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / People / Johan Luthman
Person

Johan Luthman

Tracked across 3 events · 20 articles · First seen Apr 13, 2026 · Last active May 28, 2026

Sentiment
0
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (3)
4 0
Tech
H. Lundbeck A/S Presents Neurology Data
Impact: Johan Luthman, EVP and Head of Research & Development at Lundbeck, commented on the progress in neuroscience and Lundbeck's approach to drug development.
Apr 13, 2026 · 6 articles
4 0
Business
H._Lundbeck asedebart Japan ODD
Impact: Johan Luthman, EVP and Head of Research and Development at Lundbeck, expressed satisfaction with the orphan drug designation, highlighting the company's commitment to rare diseases.
May 18, 2026 · 7 articles
4 0
Business
H. Lundbeck receives South Korea migraine drug approval
Lundbeck announced that the South Korea — Ministry of Food and Drug Safety of South Korea has granted marketing authorization for eptinezumab (Vyepti) for the preventive treatment of migraine in adults. This approval is a…
Impact: Johan Luthman, EVP and Head of Research and Development at Lundbeck, commented on the significance of the approval for migraine patients in South Korea.
May 26, 2026 · 7 articles
NEWSDESK
Track Johan Luthman live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.